Noul, an AI-based diagnostic platform company, announced Tuesday its expansion into the European market through a supply agreement with Germany’s Limbach Group SE, the country’s largest diagnostic laboratory network.
Under the agreement, Noul will supply its AI-powered blood analysis solution, miLab BCM, and malaria diagnostic solution, miLab MAL, to multiple Limbach Group labs through 2026.
Noul has signed a supply agreement with Germany’s Limbach Group SE to provide its AI-powered blood analysis solution, miLab BCM (shown in picture), and malaria diagnostic solution, miLab MAL, to multiple labs through 2026 as part of its European market expansion. (Courtesy of Noul)
Founded in 1979, Limbach Group operates 30 integrated laboratories across Germany, generating annual revenues of approximately 1.7 trillion won ($1.2 billion). The network employs over 5,000 staff, including 300 clinical experts, and specializes in immunodiagnostics, hematology, and infectious disease diagnostics.
“This is a significant milestone as our first partnership with a major diagnostic lab chain in Europe,” said David Lim, CEO of Noul. He emphasized the cost-effectiveness of miLab BCM, the world’s first fully automated compact blood analysis solution, which is designed to improve workflows in advanced markets like Europe.
Noul recently supplied miLab BCM to major hospitals and diagnostic centers in Italy, marking its first European sales. While the names of the institutions remain undisclosed due to confidentiality agreements, a Noul official noted that the delivery of Noul’s malaria diagnostic solution, miLab MAL, to Italy in May paved the way for its expansion.
The official highlighted that the recent German partnership with Limbach represents a "bigger milestone" given the company's extensive network and presence. “The partnership with Limbach lays the groundwork for Noul to extend its reach across Europe, starting with Germany and expanding to Switzerland, the Netherlands, and other countries,” the official explained.
Lim added, “Following the supply of our validated malaria and blood analysis solutions, we plan to expand our portfolio in Europe, including our cervical cancer diagnostic solution, miLab CER, recognized by WHO-UNITAID.”
Noul’s miLab BCM is a fully automated, AI-driven blood analysis system that uses proprietary NGSI (next-generation solid-staining imaging) technology to automate image acquisition, analysis, and diagnostics, with applications extending to leukemia and other blood cancers. Designed to replace approximately 680 million global peripheral blood smear (PBS) tests, it requires minimal infrastructure and specialized manpower.
The German in-vitro diagnostics market, the largest in the EU, is valued at an estimated 4 trillion won and continues to grow, driven by advanced infrastructure, aging demographics, and rising chronic disease rates.
Meanwhile, Noul has expanded into the ASEAN market through an exclusive supply agreement with Indonesian medical device distributor PT Kirana Jaya Lestari, providing its miLab BCM to hospitals and screening centers across Indonesia. The company has obtained regulatory approvals for miLab BCM in Europe, the Middle East, and ASEAN, and is currently undergoing the FDA approval process.